Solubility and Dissolution Enhancement of Lornoxicam by Surface Solid Dispersion

Abstract

Lornoxicam (LOX) is (NSAID); it is a crystalline powder that ranges in color from orange to yellow and is practically insoluble in water. The aim of this study is to increase the solubility and dissolution of LOX using the surface solid dispersions SSD approach by employing hydrophilic-water insoluble carriers, such as Aerosil 200, Croscarmellose Sodium (CCS), Sodium Starch Glycolate (SSG), Crospovidone and Avicel® PH101.

To determine the best drug-carrier interaction, the SSD formulations of LOX were preparing by kneading in various drug: carrier weight ratios (1:1, 1:3, 1:5). They were then assessed for their yield, content of drug, solubility in water, in-vitro release in 7.4 phosphate buffer saline, powder X-ray diffraction, and Fourier Transform Infrared Spectroscopy (FTIR). Most of the prepared SSD formulae demonstrated increased drug solubility.

Crospovidone had the most significant results, with a high percentage of yield (98%), high drug content (95.2%), and a 147.6-fold increase in solubility over pure drug solubility with an enhanced dissolution rate. Lornoxicam was transformed into an amorphous form absence of any chemical interaction with the carrier. Therefore, SSD technology successfully increased the solubility and the dissolution rate of LOX.

or read it here

Riyam Sadiq Jafer, Hanan Jalal Kassab. Solubility and Dissolution Enhancement of Lornoxicam by Surface Solid Dispersion. Iraqi Journal of Pharmaceutical Sciences [Internet]. 2025 Jun. 25 [cited 2025 Jul. 2];34(2):239-4. Available from: https://www.bijps.uobaghdad.edu.iq/index.php/bijps/article/view/3827

Read more interesting articles on Lornoxicam here:

• Dissolve Pain in Seconds: The Advantage of F-MELT®in Lornoxicam Fast Disintegrating Tablets
• Design and Optimization of Lornoxicam Dispersible Tablets Using Quality by Design (QbD) Approach
• Design, characterization and in vivo performance of solid lipid nanoparticles (SLNs)-loaded mucoadhesive buccal tablets for efficient delivery of Lornoxicam in experimental inflammation